The Covid-19 pandemic has accelerated the adoption and advancement of wearable technology within the medical sector. With healthcare systems worldwide confronting unparalleled obstacles, there has been a notable surge in prioritising remote monitoring and telemedicine solutions to sustain patient care while mitigating the risk of virus transmission. Wearable technologies, including smartwatches and medical-grade wearables, have become essential instruments for remotely monitoring glucose levels and managing diabetes. In line with this trend, a recent update now allows Apple Watch users to directly access glucose data from older DexCom continuous glucose monitoring (CGM) devices, further solidifying the integration of wearables into medical practices.

According to GlobalData forecasts, the wearable tech industry was worth $99.5bn in 2022 and will reach $290.6bn by 2030, expanding at a compound annual growth rate (CAGR) of 14.3% between 2022 and 2030. The market is poised for growth driven by increased sales of hearables and smartwatches. Moreover, the integration of AI holds the potential to inaugurate a new era of interactive and intelligent wearable devices, thereby enhancing user experiences. Previously, Apple Watch users relied on their iPhones to relay glucose data from Dexcom CGMs, resulting in potential delays and incomplete information due to Apple’s restrictions on third-party app refresh rates. However, with the latest update, Dexcom G7 revolutionises the user experience by enabling direct Bluetooth connectivity between the CGM, smartphone, pump, and Apple Watch, allowing for real-time glucose monitoring directly on the wrist.

The pandemic has propelled the adoption of these technologies among healthcare professionals and patients alike, paving the way for a more connected and proactive approach to diabetes management both during and beyond the pandemic. With both Dexcom and Abbott securing FDA clearances for over-the-counter CGMs, the competition in the glucose monitoring market intensifies. However, Dexcom’s strategic investment in direct-to-watch integration demonstrates its commitment to innovation and user-centric design, positioning the company as a leader in the evolving landscape of wearable health technology.